These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 27369381)

  • 1. Selectivity for strand-transfer over 3'-processing and susceptibility to clinical resistance of HIV-1 integrase inhibitors are driven by key enzyme-DNA interactions in the active site.
    Métifiot M; Johnson BC; Kiselev E; Marler L; Zhao XZ; Burke TR; Marchand C; Hughes SH; Pommier Y
    Nucleic Acids Res; 2016 Aug; 44(14):6896-906. PubMed ID: 27369381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the molecular mechanism of cross-resistance to HIV-1 integrase strand transfer inhibitors by molecular dynamics simulation and residue interaction network analysis.
    Xue W; Jin X; Ning L; Wang M; Liu H; Yao X
    J Chem Inf Model; 2013 Jan; 53(1):210-22. PubMed ID: 23231029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout.
    Osman N; Mesplède T; Oliveira M; Hassounah S; Wainberg MA; Brenner BG
    AIDS; 2018 Aug; 32(13):1773-1780. PubMed ID: 29894388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study.
    Cheung PK; Shahid A; Dong W; Lepik KJ; Montaner JSG; Brockman MA; Brumme ZL; Brumme CJ
    J Antimicrob Chemother; 2022 Mar; 77(4):979-988. PubMed ID: 35061879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV drug resistance against strand transfer integrase inhibitors.
    Anstett K; Brenner B; Mesplede T; Wainberg MA
    Retrovirology; 2017 Jun; 14(1):36. PubMed ID: 28583191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572).
    Hare S; Smith SJ; Métifiot M; Jaxa-Chamiec A; Pommier Y; Hughes SH; Cherepanov P
    Mol Pharmacol; 2011 Oct; 80(4):565-72. PubMed ID: 21719464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants.
    Smith SJ; Zhao XZ; Burke TR; Hughes SH
    Retrovirology; 2018 May; 15(1):37. PubMed ID: 29769116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The R262K substitution combined with H51Y in HIV-1 subtype B integrase confers low-level resistance against dolutegravir.
    Cutillas V; Mesplede T; Anstett K; Hassounah S; Wainberg MA
    Antimicrob Agents Chemother; 2015 Jan; 59(1):310-6. PubMed ID: 25348535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir.
    Métifiot M; Maddali K; Naumova A; Zhang X; Marchand C; Pommier Y
    Biochemistry; 2010 May; 49(17):3715-22. PubMed ID: 20334344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of resistance mutations on inhibitor binding to HIV-1 integrase.
    Chen Q; Buolamwini JK; Smith JC; Li A; Xu Q; Cheng X; Wei D
    J Chem Inf Model; 2013 Dec; 53(12):3297-307. PubMed ID: 24205814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-Hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs), novel inhibitors of HIV integrase with a high barrier to resistance.
    Desimmie BA; Demeulemeester J; Suchaud V; Taltynov O; Billamboz M; Lion C; Bailly F; Strelkov SV; Debyser Z; Cotelle P; Christ F
    ACS Chem Biol; 2013; 8(6):1187-94. PubMed ID: 23517458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular dynamics approaches estimate the binding energy of HIV-1 integrase inhibitors and correlate with in vitro activity.
    Johnson BC; Métifiot M; Pommier Y; Hughes SH
    Antimicrob Agents Chemother; 2012 Jan; 56(1):411-9. PubMed ID: 22037850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Close-up: HIV/SIV intasome structures shed new light on integrase inhibitor binding and viral escape mechanisms.
    Engelman AN; Cherepanov P
    FEBS J; 2021 Jan; 288(2):427-433. PubMed ID: 32506843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The inhibition process of HIV-1 integrase by diketoacids molecules: Understanding the factors governing the better efficiency of dolutegravir.
    El Khoury L; Piquemal JP; Fermandjian S; Maroun RG; Gresh N; Hobaika Z
    Biochem Biophys Res Commun; 2017 Jul; 488(3):433-438. PubMed ID: 28478035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterocycle amide isosteres: An approach to overcoming resistance for HIV-1 integrase strand transfer inhibitors.
    Peese KM; Naidu BN; Patel M; Li C; Langley DR; Terry B; Protack T; Gali V; Lin Z; Samanta HK; Zheng M; Jenkins S; Dicker IB; Krystal MR; Meanwell NA; Walker MA
    Bioorg Med Chem Lett; 2020 Feb; 30(3):126784. PubMed ID: 31761656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase.
    Quashie PK; Mesplède T; Han YS; Veres T; Osman N; Hassounah S; Sloan RD; Xu HT; Wainberg MA
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6223-35. PubMed ID: 24080645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of HIV-1 integrase resistance to dolutegravir and potent inhibition of drug-resistant variants.
    Li M; Oliveira Passos D; Shan Z; Smith SJ; Sun Q; Biswas A; Choudhuri I; Strutzenberg TS; Haldane A; Deng N; Li Z; Zhao XZ; Briganti L; Kvaratskhelia M; Burke TR; Levy RM; Hughes SH; Craigie R; Lyumkis D
    Sci Adv; 2023 Jul; 9(29):eadg5953. PubMed ID: 37478179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-Guided Optimization of HIV Integrase Strand Transfer Inhibitors.
    Zhao XZ; Smith SJ; Maskell DP; Métifiot M; Pye VE; Fesen K; Marchand C; Pommier Y; Cherepanov P; Hughes SH; Burke TR
    J Med Chem; 2017 Sep; 60(17):7315-7332. PubMed ID: 28737946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir.
    Quashie PK; Mesplède T; Han YS; Oliveira M; Singhroy DN; Fujiwara T; Underwood MR; Wainberg MA
    J Virol; 2012 Mar; 86(5):2696-705. PubMed ID: 22205735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 Integrase Strand Transfer Inhibitors with Reduced Susceptibility to Drug Resistant Mutant Integrases.
    Zhao XZ; Smith SJ; Maskell DP; Metifiot M; Pye VE; Fesen K; Marchand C; Pommier Y; Cherepanov P; Hughes SH; Burke TR
    ACS Chem Biol; 2016 Apr; 11(4):1074-81. PubMed ID: 26808478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.